Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for Bone Loss in HIV
NCT00061256Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Alendronate with Placebo (2 arms). Primary endpoint: Bone Mineral Density at 48 weeks. Status: completed.
02
Drugs
alendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00061256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061256.